Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
NCT01561430Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2012
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of ly2886721 in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations at 26 weeks. Started Mar 2012; status: terminated.
02
Drugs
ly2886721
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01561430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01561430.